Treatment News : New HHS HIV Treatment Guidelines Account for Cost

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » May 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


May 2, 2014

New HHS HIV Treatment Guidelines Account for Cost

Issuing an update to the February 2013 Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents, the U.S. Department of Health and Human Services (HHS) has for the first time added a section on cost considerations as related to treatment. Following the lead of the HIV Medicine Association of the Infectious Diseases Society of America, HHS also recommended testing CD4 counts less frequently for those who are doing well on antiretroviral (ARV) therapy.

The new section on cost considerations takes into account the availability of generic ARVs and provides an overview of the cost of therapy as it relates to adherence to HIV meds; it also looks into cost-sharing issues and prior authorization of therapies. The section examines how cost may be contained without ultimately dragging on the effectiveness of treatment.

HHS recommends that those who have been taking ARVs for two years or more and who have consistently had an undetectable viral load should receive a CD4 screen once a year if they have between 300 and 500 CD4s. For those with greater than 500 CD4s, screening is optional. More frequent CD4 testing is advised for those who experience virologic rebound, who develop symptoms related to HIV disease, or who develop other symptoms or begin a new drug regimen that might cause CD4s to drop.

To read the guidelines, click here.

Search: HHS, Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents, cost considerations, CD4 screening, U.S. Department of Health and Human Services.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:


[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.